RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018 Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the...

RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...

RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end    The ERADICATE Hp2 study enrolled 455 patients with...

RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement From Broadfin Capital LLC TEL-AVIV, Israel, Dec. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...